rs1536798

Variant summary

Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1

The NM_004972.4(JAK2):​c.1056+1143C>A variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.602 in 151,982 control chromosomes in the GnomAD database, including 29,667 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.

Frequency

Genomes: 𝑓 0.60 ( 29667 hom., cov: 32)

Consequence

JAK2
NM_004972.4 intron

Scores

2

Clinical Significance

Not reported in ClinVar

Conservation

PhyloP100: 0.194

Publications

10 publications found
Variant links:
Genes affected
JAK2 (HGNC:6192): (Janus kinase 2) This gene encodes a non-receptor tyrosine kinase that plays a central role in cytokine and growth factor signalling. The primary isoform of this protein has an N-terminal FERM domain that is required for erythropoietin receptor association, an SH2 domain that binds STAT transcription factors, a pseudokinase domain and a C-terminal tyrosine kinase domain. Cytokine binding induces autophosphorylation and activation of this kinase. This kinase then recruits and phosphorylates signal transducer and activator of transcription (STAT) proteins. Growth factors like TGF-beta 1 also induce phosphorylation and activation of this kinase and translocation of downstream STAT proteins to the nucleus where they influence gene transcription. Mutations in this gene are associated with numerous inflammatory diseases and malignancies. This gene is a downstream target of the pleiotropic cytokine IL6 that is produced by B cells, T cells, dendritic cells and macrophages to produce an immune response or inflammation. Disregulation of the IL6/JAK2/STAT3 signalling pathways produces increased cellular proliferation and myeloproliferative neoplasms of hematopoietic stem cells. A nonsynonymous mutation in the pseudokinase domain of this gene disrupts the domains inhibitory effect and results in constitutive tyrosine phosphorylation activity and hypersensitivity to cytokine signalling. This gene and the IL6/JAK2/STAT3 signalling pathway is a therapeutic target for the treatment of excessive inflammatory responses to viral infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2020]
INSL6 (HGNC:6089): (insulin like 6) The protein encoded by this gene contains a classical signature of the insulin superfamily and is significantly similar to relaxin and relaxin-like factor. This gene is preferentially expressed in testis. Its expression in testis is restricted to interstitial cells surrounding seminiferous tubules, which suggests a role in sperm development and fertilization. [provided by RefSeq, Jul 2008]

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -12 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.93).
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.854 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
JAK2NM_004972.4 linkc.1056+1143C>A intron_variant Intron 8 of 24 ENST00000381652.4 NP_004963.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
JAK2ENST00000381652.4 linkc.1056+1143C>A intron_variant Intron 8 of 24 1 NM_004972.4 ENSP00000371067.4
JAK2ENST00000636127.1 linkc.1056+1143C>A intron_variant Intron 8 of 15 5 ENSP00000489812.1

Frequencies

GnomAD3 genomes
AF:
0.601
AC:
91322
AN:
151862
Hom.:
29619
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.861
Gnomad AMI
AF:
0.579
Gnomad AMR
AF:
0.532
Gnomad ASJ
AF:
0.579
Gnomad EAS
AF:
0.368
Gnomad SAS
AF:
0.504
Gnomad FIN
AF:
0.545
Gnomad MID
AF:
0.538
Gnomad NFE
AF:
0.494
Gnomad OTH
AF:
0.582
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome
AF:
0.602
AC:
91435
AN:
151982
Hom.:
29667
Cov.:
32
AF XY:
0.599
AC XY:
44494
AN XY:
74274
show subpopulations
African (AFR)
AF:
0.862
AC:
35778
AN:
41522
American (AMR)
AF:
0.531
AC:
8108
AN:
15258
Ashkenazi Jewish (ASJ)
AF:
0.579
AC:
2010
AN:
3470
East Asian (EAS)
AF:
0.369
AC:
1906
AN:
5162
South Asian (SAS)
AF:
0.504
AC:
2433
AN:
4826
European-Finnish (FIN)
AF:
0.545
AC:
5744
AN:
10548
Middle Eastern (MID)
AF:
0.507
AC:
149
AN:
294
European-Non Finnish (NFE)
AF:
0.494
AC:
33544
AN:
67878
Other (OTH)
AF:
0.585
AC:
1236
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.503
Heterozygous variant carriers
0
1620
3240
4860
6480
8100
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
726
1452
2178
2904
3630
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.536
Hom.:
2441
Bravo
AF:
0.610
Asia WGS
AF:
0.503
AC:
1747
AN:
3474

ClinVar

Not reported in ClinVar

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.93
CADD
Benign
3.0
DANN
Benign
0.56
PhyloP100
0.19
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs1536798; hg19: chr9-5056931; API